Compare LSE & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LSE | ATYR |
|---|---|---|
| Founded | 2007 | 2005 |
| Country | China | United States |
| Employees | N/A | 59 |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.4M | 83.3M |
| IPO Year | N/A | N/A |
| Metric | LSE | ATYR |
|---|---|---|
| Price | $4.63 | $0.82 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $4.20 |
| AVG Volume (30 Days) | 28.8K | ★ 1.2M |
| Earning Date | 02-13-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $61.76 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.80 | $0.64 |
| 52 Week High | $9.78 | $7.29 |
| Indicator | LSE | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 43.55 | 43.03 |
| Support Level | $4.11 | $0.82 |
| Resistance Level | $5.43 | $0.85 |
| Average True Range (ATR) | 0.61 | 0.06 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 0.42 | 16.04 |
Leishen Energy Holding Co Ltd is a provider of clean-energy equipment and integrated solutions to the oil and gas industry, with a commitment to providing customers with high-performance, safe, and cost-effective energy solutions. The company's business segments include clean-energy equipment, oil and gas engineering technical services, new energy production and operation, and digitalization and integration equipment. A majority of its revenue is generated from the clean-energy equipment segment, which supplies various equipment, such as reciprocating compressor units, expansion units, wellhead heating systems, wellhead safety control systems, oil-water separation systems, natural gas online sampling systems, oil and gas skid-mounted equipment, and polymer flexible composite pipes.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).